The Convergence of Science and Hope

Argos Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. The Company has developed a pipeline of products based on its proprietary Arcelis technology platform.

View the Arcelis Platform

hp_adapt_its_personal

Argos in The News

8717088659698656515fad29f7-f96a-4a15-82e1-bc62530a444b37630afb-c541-47b6-84cf-44fc311a17969c0d68ea-93be-4ea0-99ce-c94ddf466d69ARGS_News_2016_1_20_General_Releases.pdfARGS_News_2015_12_10_General_Releases.pdfARGS_News_2015_12_9_General_Releases.pdf1657317693143341232016-1-20T8:30:0-5:02015-12-10T8:0:0-5:02015-12-9T8:30:0-5:0950920946488946272General ReleasesGeneral ReleasesGeneral ReleasesArgos Therapeutics to Host Conference Call With Principal Investigator Dr. Robert Figlin on Thursday, December 10, 2015 at 5:00pm ESTCompany Will Meet With Investors to Discuss the Development of Immunotherapies Based on Arcelis(R) Technology PlatformDr. Lee F. Allen Joins Argos Therapeutics as Chief Medical OfficerIndependent Data Monitoring Committee Recommends Continuation of ADAPT Phase 3 Clinical Trial of AGS-003 for Metastatic Renal Cell Carcinoma Following Second Planned Interim AnalysisArgos Therapeutics to Participate in the ROTH Immuno-Oncology Corporate Access Day122122122201620152015No Error0

Dr. Lee F. Allen Joins Argos Therapeutics as Chief Medical Officer
Read more

Independent Data Monitoring Committee Recommends Continuation of ADAPT Phase 3 Clinical Trial of AGS-003 for Metastatic Renal Cell Carcinoma Following Second Planned Interim Analysis
Read more

Argos Therapeutics to Participate in the ROTH Immuno-Oncology Corporate Access Day
Read more

> More News & Events >>>

1999

When Our Company Was Founded

2006

First Arcelis product (AGS-003) clinical trial initiated in mRCC

2013

Phase 3 mRCC ADAPT Study Launched

180

Newly diagnosed RCC patients daily in the US, of which ~ 30 will present with stage IV or metastatic RCC